ClinicalTrials.gg
RecruitingNCT05970783Updated Oct 17, 2024

A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease

A Phase 3 interventional study of Jincaopian Tablets and Placebo in Chronic Pelvic Pain, sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2022, registered Jul 2023).
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
414
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pelvic Pain with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Pelvic Pain · China.

Planned enrollment
Largest of 12
414 · median 198
Started
2022
with 1 other
Phase 3
Only one
of the 14
Registered
11th of 14
by date
Lead sponsor
2 of 14
Beijing Konruns Pharmaceutical Co., Ltd.

Among the 14 studies in Pelvic Pain with a site in China, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 3, and was the 11th registered.

Pelvic Pain

377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

5 of the 14 studies in Pelvic Pain with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pelvic Pain with a site in China, or all of them as a file.
02

Study summary

The objective of this phase III trial to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease

Read the detailed description

Chronic pelvic pain is the major sequela of pelvic inflammatory disease and it's a common, burdensome, and costly condition that disproportionately affects women. This multicenter, randomized, double-blind, dose-parallel, placebo-controlled phase III clinical trial is designed to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease. In this trial, 414 subjects were enrolled and randomized to either "Jincaopian Tablets" group, or the "placebo" group in a 2:1 ratio. The treatment period is 12 weeks and the follow-up period is 4 weeks.

03

Conditions studied

  • Chronic Pelvic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease;
  • The average VAS score of pain in the week before enrollment is ≥4;
  • The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points);
  • Women aged 18 to 50 (including 18 and 50) with a history of sexual life;
  • Voluntarily participate in this clinical trial, give and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Pelvic inflammatory disease (acute attack);
  • Pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 6 months after the trial;
  • Previously diagnosed with cervical intraepithelial neoplasia, primary/secondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases;
  • Complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis;
  • Gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms;
  • Placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages;
  • Received related treatment or took drugs with similar functions and indications within 14 days before the introduction;
  • Liver function: or AST>1.5 times the value;Renal function:Scr>1.0 times the upper limit of normal value;
  • Serum CA125 and erythrocyte sedimentation > 1.1 times the upper limit of normal value.
  • Combined with serious cardiovascular, cerebrovascular, hematopoietic system and other serious diseases;
  • Have an allergic history to the experimental drug;
  • Have a long history of alcoholism or drug abuse;
  • Intellectual disabilities or mental disorders;
  • Participated in other clinical trials within the past 3 months;
  • The investigator believes that it is not suitable to participate in this clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
414 participants (estimated)

Study arms

  • Experimental
    Jincaopian Tablets group

    Patients receive Jincaopian Tablets 0.6g/day for 12 weeks.

    Drug: Jincaopian Tablets

  • Placebo comparator
    Placebo group

    Patients receive a placebo 0.6g/day for 12 weeks.

    Other: Placebo

Interventions

  • DrugJincaopian Tablets

    Jincaopian Tablets 0.2g tid p.o.

    Also known as: ZY5301

  • OtherPlacebo

    Placebo 0.2g tid p.o.

06

What researchers measure

Primary outcomes

  1. Pain disappearance rate after 12 weeks of treatment

    The pain disappearance referred to the Visual Analogue Scale (VAS) score becoming 0-1 points, and was no longer greater than or equal to 2 points at any subsequent evaluation. The pain disappearance rate was defined as the proportion of patients who achieved a pain disappearance after treatment.

    Time frame: 12 Weeks

Secondary outcomes

  1. Pain disappearance rate after 4 and 8 weeks of treatment

    The pain disappearance referred to the Visual Analogue Scale (VAS) score becoming 0-1 points, and was no longer greater than or equal to 2 points at any subsequent evaluation. The pain disappearance rate was defined as the proportion of patients who achieved a pain disappearance after treatment.

    Time frame: 8 Weeks

  2. Change of weekly average Visual Analogue Scale (VAS) score from baseline after 12 weeks of treatment

    Visual Analogue Scale (VAS) was used to evaluate pelvic pain degree. The VAS score ranged from 0 to 10, and a higher score represented greater pain intensity. The average VAS value for a week was calculated by dividing the sum of the scores for each day of the week by the number of days the score was recorded.

    Time frame: 12 Weeks

  3. The area under the VAS score-time curve

    AUC under the curve to evaluating pain levels

    Time frame: 12 Weeks

  4. McCormick Scale

    The McCormack scale was used to score the patient's physical signs. The total score is 36 points, rated from twelve aspects including uterine tenderness (divided into four quadrants), abdominal tenderness or rebound pain (divided into four quadrants), left or right adnexal tenderness, uterine tenderness, and cervical lifting and swinging pain. The scoring criteria was as following: no pain is 0 points; Mild pain without facial expression changes and muscle tension is 1 point; Pain accompanied by facial expressions and muscle tension is 2 points; Pain drama is 3 points.

    Time frame: 12 Weeks

  5. General quality of life (Short Form-12) scale

    The Short Form-12 is an abbreviated version of the original 36-item QOL questionnaire. It comprises 12 items with a mental component summary (MCS) and a physical component summary (PCS). Possible scores for mental and physical health-related QOL subscales range from 0 to 100 points, and a higher score is interpreted as better QOL.

    Time frame: 12 Weeks

  6. Disease efficacy evaluation

    Disease efficacy was determined based on the change of the clinical signs and symptoms. Based on the evaluation criteria, the Disease efficacy was recorded as Clinical recovery, significant effect, effectiveness, and ineffectiveness. Clinical recovery: The symptoms and signs disappear, and the integral values of symptoms, signs, and auxiliary examinations decrease by ≥ 95%. Significant effect: The symptoms and signs are significantly reduced, with a reduction of ≥ 70% and\<95% in the score of symptoms, signs, and auxiliary examinations. Effective: Symptoms and signs have been alleviated, with a reduction of ≥ 30% and\<70% in symptom, sign, and auxiliary examination scores. Invalid: No reduction or aggravation of symptoms and signs, with a decrease of\<30% in the score of symptoms, signs, and auxiliary examinations

    Time frame: 12 Weeks

  7. Adverse events (AEs)

    Incidence of treatment-related AEs

    Time frame: 12 Weeks

07

Study locations

1 of 1 sites recruiting
  • Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University
    Beijing, Beijing, China
    Recruiting
    • Xiuxiang Teng · Contacttengxx@126.com · +86 010-87906734
    • Xiuxiang Teng · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Mar 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Aug 1, 2023
StartActual
Nov 8, 2022
Primary completionActual
Mar 11, 2024
CompletionEst.
Apr 2025
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05970783
Lead sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Nov 8, 2022
Primary completion
Mar 11, 2024
Completion
Apr 2025 (estimated)
Last update
Oct 17, 2024

Study contacts

Xiuxiang Teng
Contact
tengxx@126.com
+86 010-87906734
Xiuxiang Teng
principal investigator · Beijing Hospital of Traditional Chinese Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion